

Lenvatinib

PRELIMINARY SCORE


CURATIVE


NON-CURATIVE

OS


ADJUSTMENTS


Quality of life







Serious and disabling adverse effects





Other adjustments





Lenvatinib

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

4

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: Treatment of adults with advanced renal cell carcinoma in combination with everolimus following one prior vascular endothelial growth factor (VEGF)-targeted therapy

Experimental Arm: Lenvatinib + Everolimus

Control Arm: Everolimus



